Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

HomeNativisNativis Publishes Abstract on Voyager System for Patients with rGBM at 2017 ASCO Annual Meeting

Nativis Publishes Abstract on Voyager System for Patients with rGBM at 2017 ASCO Annual Meeting

Interim results presented for first-in-human study in first of 2-stage study

Nativis, Inc., today announced the release of an abstract on its Nativis Voyager® system for use in patients with recurrent glioblastoma multiforme (rGBM). The abstract will be published online during the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2017, in Chicago, IL. Abstracts can be found here.

The Nativis Voyager system is a non-invasive investigational device that delivers ultra-low radio frequency energy (ulRFE™) profiles to the brain. The ulRFE profiles are derived from changes in molecular electrostatic surface potential. The Voyager system is being studied in a first-in-human study to assess the safety and feasibility of treatment for recurrent glioblastoma multiforme.

In the publication entitled “A Feasibility Study of the Nativis Voyager™ System in Patients with Recurrent Glioblastoma Multiforme (GBM): Interim results of first-in-human study,” the authors, Garni Barkhoudarian, Charles Cobbs, Edward McClay, Brian Vaillant, J. Paul Duic, L. Burt Nabors, Benjamin M. Ellingson, Deborah Sheffield, Santosh Kesari, highlighted the interim results of the first part of a 2-stage study. This first study enrolled 14 patients at four clinical trial sites across the United States, in which 11 subjects were followed per protocol, with 3 subjects dropping out for reasons not associated with the study. In the first two months of treatment, 2 of the 11 subjects were Avastin-naïve and exhibited a partial response. After 6 cycles (24 weeks) of treatment, the local sites reported 2 patients were progression free. No serious adverse events associated with the investigational therapy were reported.

“We are honored to have our first-in-human study recognized by ASCO as we continue to pioneer our novel ulRFE technology,” commented Chris Rivera, Nativis President and Chief Executive Officer. “The interim data from this feasibility study provide an encouraging outlook for the Voyager system, which appears to be feasible and safe for the treatment of recurrent GBM. With these data in hand, we look forward to moving forward into the second and final stage of the study.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy